SCHEMBL6080252

SCHEMBL6080252

Cc1c(C(=O)O)nc2c(N)cc(CCc3ccccc3)cc2c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 3/20 0.45
RNASEH1 O60930 2/20 0.41
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
BACE1 P56817 1/20 0.37
OPRL1 P41146 1/20 0.37
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
ALOX5 P09917 1/20 0.35
LDHA P00338 1/20 0.35
LDHB P07195 1/20 0.35
EGLN2 Q96KS0 1/20 0.35
EGLN1 Q9GZT9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
MCL1 Q07820 1/20 0.34
BCL2A1 Q16548 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6080633 0.89 PTGFR (0.39)
SCHEMBL6080655 0.83 ALOX5 (0.50) P2RX3RNASEH1ALOX5KDM4E
SCHEMBL6080506 0.82 P2RX3 (0.43) P2RX3RNASEH1EGLN2EGLN1KDM4E
SCHEMBL6080431 0.81 DHODH (0.40) RNASEH1MEN1KMT2AKDM4EALDH1A1
SCHEMBL6079524 0.79 TDP1 (0.44) MEN1KMT2ALDHALDHBKDM4E
SCHEMBL6081107 0.79 KDM4E (0.41) MEN1KMT2ALDHALDHBKDM4E
SCHEMBL6080260 0.79 KDM4E (0.34) MEN1KMT2ALDHALDHBKDM4E
SCHEMBL6080240 0.78 MAPT (0.40) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL6079991 0.78 P2RX3 (0.47) P2RX3RNASEH1KMT2AKDM4EALDH1A1
SCHEMBL6081075 0.78 RNASEH1 (0.44) P2RX3RNASEH1LDHALDHB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US claimed
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NEURO3D (FR) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183909-A1 Compositions derived from quinoline and quinoxaline, preparation and use thereof NQO1, NQO2, RECQL P2RX3 465/4885RNASEH1 2268/4885MEN1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.